understanding of the factors that influence disease transmission is essential to development of strategies to prevent AIDS transmission from HIV-infected mothers to their children.
Breast feeding is known to affect the transmission of viral infections from mother to child. Human milk contains a number of Ig and non-Ig factors that can inhibit the replication of pathogenic microbial agents (6-9). Conversely, human milk can contain viruses, such as cytomegalovirus and human T-cell leukemia virus, that can initiate neonatal infection (1 0-12); indeed, anecdotal reports have described the isolation of HIV from breast milk and the apparent infection of infants feeding on the milk of mothers who recently had sero-converted (1 3-15). The possible association between breast feeding and HIV transmission poses a medical dilemma, because breast-fed infants generally display lower rates of other infections than do infants fed bovine milk-based formula (16) (17) (18) (19) (20) . The dilemma is particularly acute in the case of infants living in the less developed countries, because numerous studies have documented increased rates of infant mortality when bovine milk formula is substituted for human milk as the principal source of neonatal nutrition (21) (22) (23) (24) . An improved understanding of factors in human milk that may modulate HIV infection might lead to the reassessment of the potential risks and benefits of breast feeding in populations with higher rates of maternal HIV infection.
Milk may modulate infection in neonates through several mechanisms. In addition to specific Ig and cell-mediated immune responses, human milk contains macromolecules that inhibit the binding of pathogenic agents to their host receptors. Such protective activity has been attributed to milk glycolipids (25) and oligosaccharides (26) (27) (28) . The existence of analogous inhibitors of virus-receptor interactions could be of particular importance in the case df HIV infection, in light of the antigenic variation of neutralizing epitopes on the viral envelope and the relative conservation of the sites involved in receptor interactions (29--, \ 
I).
The CD4 molecule is the major receptor for HIV binding to T-helper lymphocytes and, possibly, to other cells that support HIV replication (32) (33) (34) . Because the viral envelope is heavily glycosylated, it is likely that glycosyl groups on the envelope are important determinants of viral-cellular interactions, and that exogenous glycoconjugates can modulate HIV interaction with its receptor (35) (36) (37) (38) (39) (40) . The CD4 receptor molecule has been extensively characterized by means of its reactions with HIV envelope glycoprotein (gp120) and with MAb that bind at specific CD4 epitopes (3 1, 4 1, 42), including the gp 120 binding site.
We used a solid-phase assay system to demonstrate that whole human milk inhibits the interaction of CD4 with MAb that bind at or near the site of HIV attachment and inhibits the binding of recombinant gp120 to CD4. We then purified milk samples, Milk and Serum Samples. Milk samples from healthy, HIVseronegative mothers were obtained from the Central Massachusetts Regional Milk Bank, The Medical Center of Central Massachusetts, Worcester, MA, and samples represented a broad spectrum of human milk with regard to the stage of lactation, age of the mother, and parity. Serial samples during an 80-d period were obtained from a healthy eastern Massachusetts La Leche League volunteer. Maryland samples were collected from healthy women who recently had delivered children at the Johns Hopkins Hospital in Baltimore. Milk samples also were obtained within 1 wk postpartum from HIV-seropositive and HIV-seronegative mothers living in Cite Soleil, Haiti. Protocols and consent forms used during milk collection were approved by the Human Studies Committees of the respective parent institutions. All milk samples were stored at -70°C. Fresh, unprocessed bovine milk samples, obtained from cows from Maryland and Massachusetts, were immediately frozen and tested without additional processing. Pasteurized bovine milk was obtained commercially.
Serum samples were obtained from 23 HIV-seropositive and HIV-seronegative individuals residing in the Baltimore area.
CD4 Binding Assays. Recombinant CD4 was diluted to 0.25 mg/L in 60 mmol/L carbonate buffer, pH 9.6, and immobilized on wells of polyvinyl microtiter plates by incubation at 4°C for 14 h. Unbound CD4 was cleared from the wells in an automated washer (Skatron Microwash I; Skatron, Inc., Sterling, VA) by five washes with PBST (10 mmol/L phosphate buffer, pH 7.4, in 150 mmol/L NaCl containing 5 g/L Tween 20).
A 100-pL aliquot of the milk or milk fraction was incubated with an equal volume of OKT4A diluted 1:4000 in PBST. After incubation for 1 h at 37"C, 50-pL aliquots were added to duplicate or triplicate wells coated with CD4 and an equal number of wells coated with buffer alone. After incubation for an additional 2 h at 37"C, the wells were washed five times with PBST. The amount of bound MAb was quantified by reaction with peroxidase-labeled goat anti-mouse IgG and, after another washing step, by reaction with H202-o-phenylene diamine. The amount of color generated by the enzyme-substrate reaction was measured in a microplate calorimeter at 405 nm. For each dilution of milk or of a milk fraction, a specific binding activity was calculated by subtracting the OD generated in the buffer-coated control well from that generated in the CD4-coated well. The specific binding activity was represented as a percentage according to the following formula:
where SA, is the sp act of the milk fraction, and SAb is the mean sp act of buffer control samples measured in the same microtiter plate. The inhibitory activity of the whole milk samples was calculated by testing the milk at several log,,-fold dilutions and interpolating to the concentration that resulted in 50% inhibition of OKT4A-CD4 binding; this activity was expressed as 50% minimum inhibitory concentration.
In other experiments, CD4-reactive MAb were substituted for OKT4A. The OKT4B, OKT4D, OKT4E, OKT4F, and MT 15 1 antibodies were diluted 1 :4000, 1 :2000, 1 :400, 1 :400, and 1 :2000, respectively, and used as described above for OKT4A. These dilutions were selected to yield OD equivalent to that yielded by OKT4A in the absence of added inhibitor. OKT4B, which is an IgM-class antibody (34) , was quantified by reaction with peroxidase-labeled anti-murine IgM, and the other MAb were measured by reaction with peroxidase-labeled anti-murine IgG. The percentage inhibition was calculated as for OKT4A.
Additional assays were performed in which gp 120 and monoclonal anti-gp I20 antibody were substituted for the anti-CD4 antibodies. After dilution to a concentration of 4 mg/L, gp120 was incubated with an equal volume of milk fractions for 20 min at room temperature. The mixture was transferred to microtiter wells coated with CD4 or buffer, as described above, and incubated for 1 h at 37°C. After washing, the amount of gp 120 bound to the CD4 was quantified by reaction with 110-1 MAb antibody to gp120 and anti-murine IgG. The percentage inhibition was calculated as described above for the OKT4A assay system.
Purification of Human Milk Fractions. Human milk oligosaccharide fractions. Previously frozen pooled human milk (1 L) was centrifuged at 4°C at 3000 x g for 1 h. The cream was removed, and the skimmed milk filtered through glass wool. The filtrate was mixed with an equal amount of ice-cold acetone, stirred overnight at 4"C, and centrifuged at 3000 x g for 45 min (46). The clear supernatant was reduced to approximately 0.2 L by rotary evaporation, and the resultant aqueous solution was applied to a 1-L charcoal-Celite column (charcoal: Norit decolorizing carbon and Celite 545; Fisher Scientific). After exhaustive washing with distilled water and 0.86 mol/L ethanol (aq.), the oligosaccharide fraction was eluted from the column with 8.6 mol/L ethanol (aq.). The eluate was passed through anion exchange resin AG I-X2 (formate) (BioRad, Richmond, CA) to yield the neutral oligosaccharide fraction. The acidic oligosaccharides were eluted from the resin with 1 mol/L formic acid (27) . This procedure yielded approximately 6 g of neutral fraction and 18 mg of acidic oligosaccharide.
Human milk lipidfractions. Milk was extracted with 20 volumes of chloroform/methanol(2: I), filtered, and dried. The lipid was then partitioned between hexane and 15 mol/L aqueous ethanol. FFA were removed from the hexane fraction by washing with methanolic ammonia, and the fatty acids were recovered by acidifying the methanol and extracting the protonated fatty acids with hexane. The ethanol fraction was subjected to Folch partition; the upper phase lipids were isolated on a reversedphase column and then separated on DEAE Sepharose (Pharmacia, Uppsala, Sweden) into the neutral glycolipids and the anionic glycolipids (the ganglioside fraction) (47) . The Folch lower phase lipids were separated on a Unisil silicic acid column (Clarkson Chemical, Williamsport, PA) into the residual nonpolar lipid fraction, the lower phase glycolipid fraction, and the phospholipid fraction (48) .
Human milk protein fractions. Protein (or macromolecular) fractions were prepared as outlined in Figure 1 : cream was separated from the milk by centrifugation at 3000 x g for 1 h at 4°C and removed by filtration through glass wool. The resulting skimmed milk was passed through a 0.45-pm filter; the filtrate and retentate were passed separately through a 10 000-D cutoff ultrafilter, and the retentates were washed three times with distilled water (diafiltration). Each of the retentates was then lyophilized and weighed. Seven hundred and fifty mg of each of these protein fractions was purified through a 0.04-L concanavalin A-sepharose affinity column. The column was washed with 0.2 L of PBS (10 mmol/ L NaH2P04, 100 mmol/L NaCl, pH 7.0); 0.2 L of buffered 1 mol/L NaCl; and 0.2 L of a solution containing 1 mol/L methyl glucoside, 1 mol/L methyl mannoside, and 1 mol/L NaCl, pH 7.0. All fractions were subjected to diafiltration using a 100 000-D membrane (Amicon, Danvers, MA) followed by dialysis and lyophilization.
Chromatographic Separations. The protein fraction with the highest activity was further purified through a Sephadex G-200 SF molecular sieving column. A total of 288 mg of sample, dissolved in running buffer (1 0 mmol/L Tris, 100 mmol/L NaCl, 250 mmol/L EDTA), was applied to a column with a void volume of 0.75 L, and the material was chromatographed at a flow rate of 0.04 L/h. Three major peaks, one of which was the void volume, and several minor peaks appeared when the absorbance of the column emuent was measured at 280 nm. The active protein fraction was also analyzed by means of ion exchange chromatography. A 1-mL aliquot was dissolved in buffer, pH 7.4, and the sample was applied to a 2-mL column of DEAE-Sephacryl. Fractions were eluted by means of a stepwise gradient of increasing concentrations of NaCl, pH 7.4. The resulting eluates were tested for activity by the CD4-OKT4A inhibition assay.
Isoelectric Focusing. The protein fraction of another 0.15-L sample of pooled human milk was prepared as above: the cream was removed by centrifugation, and the macromolecular (protein) fraction was isolated from the skimmed milk by diafiltration through a 10 000-D ultrafilter. This protein fraction was separated by high-resolution preparative isoelectric focusing in a Rotofor apparatus (BioRad). The protein fraction was made 10 g/L with ampholytes (pH 3-10) in 0.05 L distilled water and was resolved at 16 W for 4 h. The 20 resulting fractions each represented isoelectric points of between 3 and 10. After dialysis and lyophilization, these fractions also were tested for their ability to inhibit CD4 binding. PAGE. The 20 fractions described above from the Rotofor apparatus were reduced and denatured in the presence of SDS, and the components were resolved by electrophoresis through a 4-12% polyacrylamide gel slab in a discontinuous gradient (49) . The resolved bands were visualized with silver stain (New England Nuclear, Boston, MA), and the carbohydrate-containing material was detected with PAS (50) .
Free Soluble CD4 Levels. We performed assays to determine levels of free CD4 in the milk samples. The OKT4B IgM MAb was diluted 1:800 and bound to the wells of the microtiter plate overnight at 4°C. After the wells were washed, the milk samples were added and incubated for 1 h at 37°C. The amounts of CD4 were determined by subsequent reactions with the OKT4A IgG MAb, peroxidase-labeled anti-murine IgG, and enzyme substrate, as described above. A set of standards consisting of known concentrations of recombinant CD4 was run in each assay. Enzymatic Treatments. Aliquots of the active macromolecular fractions, which had been passed through a 0.45+m filter and purified by ultrafiltration and dialysis as outlined above, were subjected to enzymatic digestion. The equivalent of 1 mL of milk (6.7 mg of macromolecular fraction) was dissolved in 1 mL of buffer containing 50 pg gentamicin sulfate and incubated with enzyme for 50 h. Digestion with neuraminidase from Vibrio cholera (0.05 U; Calbiochem, La Jolla, CA) was in water containing 1 mmol/L CaC12. Digestion with sulfatase from Patella vulgata (limpet) was in 0.05 mol/L acetate buffer, pH 5.0, at a concentration of 0.5 g (5000 U)/L. One unit of sulfatase from Aerobacter aerogenes was buffered with 0.05 mol/L Tris, pH 7.5.
Sulfatase from abalone entrails was used at a concentration of 10 000 U/L of 0.05 mol/L acetate buffer. Each digested sample was tested for CD4 binding inhibition. For each enzymatic digestion, a blank sample containing only buffer and enzyme was tested to assess the effect of residual enzymatic activity on CD4-OKT4A binding. Chemical Treatments. The chemical stability of the active milk factor was tested. Aliquots were subjected to 80°C distilled deionized water for 3 h, methanol at ambient temperature for 24 h (with and without 60 mmol/L ammonium acetate), or reductive alkylation [3 mg protein in 1 mL Tris buffer (1 moll L, pH 7.5), 10 g/L SDS] with 450 ~g DTT at 37°C for 4 h followed by 5 mg iodoacetamide at 37°C for 2 h. After dialysis and lyophilization, these fractions were tested for changes in CD4 binding inhibition.
RESULTS
All of the milk samples obtained from women living in Massachusetts, Maryland, and Haiti inhibited binding of CD4 to the OKT4A MAb (Fig. 2) . The geometric mean titer of inhibitory activity was 1 : 16 10 (95 % confidence intervals, 1 : 1 160-1 :2220). 
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Day of Collection p G l Similarly, serial samples obtained from a Massachusetts woman whose lactation was mature and well established displayed consistent inhibitory activity over an 80-d period, with titers ranging from 1:700 to 1:3000, despite variation in the level of total protein (Fig. 3) .
In contrast to the universal presence of high levels of inhibitory activity in human milk, levels of inhibitory activity in sera were 1:20 or lower (Fig. 2) . Similarly, inhibitory activity was not detected in raw or pasteurized bovine milk preparations. We found that dextran sulfate displayed inhibitory activity in this assay system at concentrations as low as 1 mg/L. Inhibitory activity was not found with diethylamino-dextran or unsubstituted dextrans at concentrations as high as 100 mg/L (Fig. 4) .
To identify the active component of human milk, we tested the inhibitory activity of isolated oligosaccharide, lipid, and protein fractions (Fig. 4) . No inhibitory activity was found in the oligosaccharide fractions, and only low levels were found in the lipid fractions. However, the protein fractions (containing all macromolecules including mucins and glycosaminoglycans) displayed high titers of inhibitory activity. Most of the activity was retained by a 0.45-hm filter, although measurable activity was found in the filtrate.
When this mixture of milk macromolecules was further fractionated by means of ultrafiltration and concanavalin A affinity Fig. 5 . Isoelectric focusing of human milk macromolecules. Pooled human milk protein was separated into 20 subfractions by preparative isoelectric focusing at 16 W for 4-5 h using a Rotofor apparatus. Each fraction was tested for total protein, using a commercially available assay (BioRad), and for CD4 inhibitory activity. chromatography (Fig. I) , the highest activity in both the filtrate and retentate subfractions of 0.45-hrn filtration was associated with the initial column eluate. Little of the active material specifically bound to concanavalin A.
The most active macromolecular fraction was applied to a Sephadex G200 SF molecular sieving column. The CD4-OKT4A inhibitory activity was found largely in the void volume, indicating that the active material has a molecular weight above 250 000 D under the native conditions used for the chromatography. Ion exchange chromatography performed with DEAE-Sephacryl indicated that most of the activity eluted between 0.2 and 0.3 moll L NaCl (aq.) (data not shown).
The pooled milk protein fraction was separated by preparative isoelectric focusing into 20 subfractions, which differed by their isoelectric points. Most of the CD4 inhibitory activity was found in fractions whose constituents had isoelectric points ranging from 9.3 to 9.6 (Fig. 5) . The bulk of the milk protein fraction, however, migrated to subfractions which were substantially more acidic. Thus, the sp act of the active fractions was 300-fold greater than that of the original milk protein preparation.
When these 20 subfractions were resolved by PAGE (Fig. 6 ), four major bands seemed to characterize the two most active fractions (lanes 18 and 19 from the left). The three bands with the highest apparent molecular weights stained positively for carbohydrate by PAS. At the top of the gel, the faint bands by silver stain were more strongly stained with PAS and showed two diffuse bands similar to those produced by the human milk mucins associated with the milk fat globule membrane.
The active fraction of the concanavalin A column separation was also characterized by means of enzymatic digestion. As depicted in Figure 7 , the activity was not affected by treatment with neuraminidase from V. cholerae. However, treatment with sulfatase from A. aerogenes resulted in a substantial reduction of OKT4A-CD4 inhibitory activity. Treatment with sulfatase from P. vulgata (limpet) caused a less striking decrease of inhibitory activity, and sulfatase from abalone entrails caused no appreciable change in activity. These enzymes did not by themselves affect CD4-OKT4A binding.
The inhibitory activity of the active fraction was greatly reduced by treatment with methanol, methanolic-HC1, or with methanol buffered with ammonium acetate. Reductive alkylation also resulted in an appreciable loss of activity. Heating in water at 80°C for 3 h, in contrast, reduced inhibitory activity only slightly.
Other MAb whose epitopes are found within the HIV binding site of the CD4 molecule were used to test the CD4 binding inhibition by the macromolecular fraction. As shown in Figure  8 , the binding of CD4 to OKT4D, OKT4E, and MT15 1 MAb was inhibited to the same extent as the binding to OKT4A had been. Binding to the OKT4B MAb was inhibited to a somewhat lesser extent. (OKT4 and OKT4F MAb did not display reproducible binding to CD4 in our assay system.) The active fraction inhibited the binding of CD4 to a recombinant HIV envelope protein as well; bound envelope protein was detected by means of a MAb directed at a gp 120 epitope located outside of the CD4 binding domain.
Assays to determine the level of free soluble CD4 in the breast milk samples indicated that none of the tested milks or active milk fractions contained detectable levels of free CD4 above the detection limit of I na/mL. Any ligand-bound CD4 would not be detected in this assay, but b o i n d c~4 in milk is less likely to competitively inhibit binding to the CD4 immobilized on a solid phase assay. Thus, CD4 in milk does not seem to be responsible for the CD4 blocking activity of human milk.
Studies of CD4 binding inhibition by milk were performed in which the solid-phase bound CD4 was incubated with milk and washed, and then inhibition of ligand binding to CD4 was measured. Because this sequence gave the same inhibition as when ligand and milk are incubated simultaneously with solidphase bound CD4, we concluded that the inhibitor of CD4 binding in human milk was acting by binding to CD4 and not to its ligands. DISCUSSION The binding of gp120, the outer coat protein of HIV, to CD4, the receptor molecule in the host cell, is thought to be a critical first step in the infection process. Our studies indicate that human milk contains high levels of a material that inhibits the interaction of CD4 with MAb that recognize HIV epitopes. This material also inhibits the binding of purified gp120 to CD4. The highly conserved nature of the portions of gp120 involved in CD4 binding suggests that this inhibitory activity may affect many strains of HIV-I and HIV-2 (29) . Indeed, the effect of the milk CD4 inhibitory activity on the replication of different strains of HIV should be the subject of additional investigations.
The inhibitory material seems to be widespread, as it was found in milk specimens from geographically and ethnically diverse populations, and was consistently present in milk samples representing a prolonged period of lactation. The absence of inhibition by bovine and several other milks (data not shown) suggests that the inhibitory activity is not due to a nonspecific effect of milk, but rather to a specific interaction with human CD4 molecules.
We were able to document that the blocking effect was not due to the presence of free soluble CD4, inasmuch as we could not detect CD4 antigen directly in the milk specimens. Our assay would not have detected bound CD4 in milk, thus the issue of whether some soluble CD4 exists in milk bound to the blocking agent has not been addressed directly; however, ligand-bound
